MaxCyte 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- MaxCyte reported 3rd quarter 2026 total revenue of $10.2 million, up 49% year over year, including $8.2 million of core revenue, up 27%, and $2 million of SPL program-related revenue.
- Core revenue included $2.8 million of instrument revenue versus $1.4 million in the 3rd quarter of 2025, $2 million of license revenue versus $1.8 million, and $3.1 million of processing assembly (PA) revenue versus $2.6 million.
- SPL program-related revenue was $2 million versus $0.4 million in the 3rd quarter of 2025, consisting of a $1 million milestone tied to pivotal trial dosing and approximately $1 million of royalty revenue.
- Gross margin was 83% versus 77%; non-GAAP adjusted gross margin, excluding inventory provisions and SPL program-related revenue, was 80% versus 81%. Operating expenses were $14.5 million versus $19.4 million, down 25%.
- MaxCyte ended the 3rd quarter with $132.7 million in cash, cash equivalents, and investments and no debt. Year-to-date net loss was approximately $18 million versus approximately $35 million in the comparable prior-year period.
- MaxCyte entered into a definitive agreement to acquire AkronBio from Arcline Investment Management. Akron is expected to generate $28 million in 2026 revenue and $7 million to $8 million of EBITDA, is cash flow positive, and has approximately 80% to 85% of revenue from specced-in programs.
- The combined company is expected to generate more than $60 million in revenue in 2026, support 5 commercially approved therapies, and have approximately 30% of revenue from commercial-stage customers. MaxCyte said its largest customer would represent approximately 14% of combined revenue versus 27% for MaxCyte standalone.
- Akron’s acquisition consideration is $151.8 million: $105 million in cash, approximately $26.8 million in MaxCyte common stock, and $20 million in guaranteed deferred payments in 2 installments of $10 million in '28 and '29. MaxCyte entered a credit facility with MidCap Financial of up to $75 million.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thank you for standing by, and welcome to the MaxCyte third quarter earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, again press star one. Thank you. I would now like to turn the call over to Eric Abdill, Investor Relations.
You may begin. Hello, everyone.
Thank you for participating in today's conference call. Joining me on the call from MaxCyte, we have Maher Masoud, President and Chief Executive Officer, Parmeet Ahuja, Chief Financial Officer, and Sean Menarguez, Senior Director of Business Development. Earlier today, MaxCyte released financial results for the third quarter ended September 30, 2026. A copy of the press release is available on the company's website. Before we begin, I need to read the following statement. Statements or comments made during this call may be forward-looking statements within the meaning of federal securities laws. Any statements contained in this call other than statements of historical fact, including those that relate to expectations or predictions of future events, results, or performance, are forward-looking statements.
Actual results may differ materially from those expressed or implied in any forward-looking statements due to a variety of factors, which are discussed in detail in our SEC filings. Except as required by applicable law, the company has no obligation to publicly update any forward-looking statements, whether because of new information, future events, or otherwise. With that, I will turn the call over to Maher.
Thank you, Eric. Hello, everyone, and thank you for joining MaxCyte's third quarter 2026 earnings call. Before I turn to our results, I want to highlight the announcement we made today, which I believe is one of the most exciting moments in our company's history. Following a competitive process, we have entered into a definitive agreement to acquire Akron Bio from Arcline Investment Management. Akron is a leading supplier of GMP-grade reagents and ancillary materials, including cytokines, growth factors, cell culture media, and cryopreservation solutions used in the cell therapy manufacturing steps immediately before and after cell engineering, including electroporation. Akron differentiates itself through its regulatory-grade quality and documentation, along with ready-to-use product formats that simplify and connect directly to cell therapy manufacturing workflows. Like MaxCyte, Akron is specced in its customers' regulated processes, with drug master files, or DMFs, referenced in their IND and BLA submissions.
Once specced in, which typically occurs in late-stage preclinical development, Akron's products become increasingly difficult to displace as programs advance through their clinical development and commercialization. Akron is specced into four commercially approved therapies, including one with a leading global pharma company, and supports four additional programs with registrational pathways. With Akron, MaxCyte triples its exposure to attractive commercial and registrational programs which are nearing approval. Beyond these late-stage assets, the combined company will be embedded in over 95 clinical-stage programs, including more than 85 from Akron, providing a broad pipeline for potential future commercial opportunities. As part of our extensive diligence process, we conducted a detailed program-by-program assessment of Akron's portfolio, evaluating individual development timelines, progression towards commercialization, and long-term revenue opportunities. This bottom-up approach reinforced our conviction in the quality of their portfolio and its long-term growth potential.
Akron also brings meaningful scale, expanding our commercial revenue footprint and extending our reach across the cell therapy workflow, including both viral and non-viral therapies. Akron's revenue is expected to be $28 million for 2026, and importantly, 80%-85% of 2025 revenue was generated from specced-in customers, including 40%-45% from commercial-stage customers. Both metrics highlight the durable and recurring nature of its revenue base. Furthermore, Akron is expected to generate approximately $7 million-$8 million of EBITDA in 2026 and is cash flow positive today, with an efficient cost structure. The acquisition will accelerate MaxCyte's path to profitability, which Parmeet will cover in more detail. Stepping back, I cannot be more excited about what this combination means for MaxCyte's next chapter.
For nearly two decades, Akron has built a reputation for quality and regulatory support that mirrors our own, and its team has earned the trust of developers, including with some of the largest biopharma companies, from the clinic through commercial manufacturing. Bringing our companies together will allow us to serve customers as a single, more integrated partner, deepen relationships across both of our customer bases, and do so from a position of greater scale and financial strength. Let me lay out our strategic rationale for acquiring Akron in more detail. First and foremost, this transaction expands MaxCyte's commercial revenue opportunity. CAR T has been a powerful proof point for our technology and a growing contributor to our financial results, and we remain very confident in the opportunity across our clinical-stage SPL portfolio, including the multiple pivotal programs we are supporting today.
Akron complements that foundation with a meaningful commercial base from day one. Together, we expect to support five commercially approved therapies, with durable recurring revenue tied to commercial-stage manufacturing and a deeper presence with large pharma. Approximately 30% of the combined company's revenue is expected to come from commercial-stage customers, providing greater revenue visibility and stability while reducing exposure to early-stage customer funding cycles and clinical development risk. While our SPL business model has demonstrated the value of revenue scaling alongside the commercial success of partner programs, the combination also meaningfully diversifies our customer base. Our largest customer is expected to represent approximately 14% of combined company revenue, compared to 27% for MaxCyte standalone. Reducing reliance on any single customer while maintaining meaningful exposure to the commercial success of approved therapies. Second, Akron expands our footprint across the manufacturing workflow and within our customers' regulatory packages.
MaxCyte technology plays a critical role in cell therapy manufacturing, and Akron's products support the steps surrounding it, from cell isolation and expansion through cryopreservation. Third, the acquisition meaningfully expands our addressable market. Our electroporation platform has primarily served non-viral programs, roughly 360 of the approximately 770 ex vivo cell and gene therapy programs we track across the U.S. and Europe. Because Akron's products are used regardless of the engineering method, the combined company can address all 770 programs, more than doubling our addressable program base. With limited customer overlap between Akron and MaxCyte of approximately 10% today, despite similar call points and end markets, we see meaningful opportunity to drive additional revenue growth through cross-selling. Together, we believe this positions MaxCyte as a broader cell therapy manufacturing partner, supporting customers from research through commercialization. From a financial standpoint, this transaction enhances MaxCyte's scale and financial profile.
On a pro forma basis, the combined company is expected to generate more than $60 million in revenue in 2026, nearly doubling MaxCyte's revenue base. Akron is profitable, expected to generate $7 million-$8 million in EBITDA with cash flow positivity today. Combined with the cost discipline established through last year's restructuring and the stable operating expense base we have maintained throughout 2026, this acquisition significantly accelerates our path to profitability. Parmit will provide more detail on today's announcement in his remarks, but let me now turn to MaxCyte's third quarter results. MaxCyte reported $10.2 million of total revenue in the third quarter, representing 49% year-over-year growth. Total revenue included $8.2 million of core revenue and $2 million of SPL program-related revenue, which consists of milestones and royalties.
Third quarter performance demonstrated the progress we have made throughout 2026, exceeding the growth expectations we established at the start of the year. Core revenue came in above our initial expectations, with 27% year-over-year growth and in line with the preliminary results we announced in October. Outperformance in the quarter was driven by stronger-than-anticipated instrument purchases by one of our partners, including purchases originally expected in the fourth quarter. We are encouraged by the strong start to this partnership and see opportunities for continued contributions as programs advance through development. Beyond this partnership, we saw healthy demand across our broader customer base, with double-digit year-over-year growth excluding this specific customer. Instruments showed strong growth in the quarter, with the funnel we outlined for the second half continuing to convert into revenue.
Processing assembly revenue significantly improved in the quarter across both SPL and non-SPL customers, delivering 20% year-over-year growth and 32% sequential growth. Importantly, looking at PA revenue on a trailing 12-month basis, we saw mid-single-digit growth compared to the second quarter, reinforcing the stabilization of PA revenue and its return to growth following the inventory drawdown and program rationalizations experienced last year. License revenue also remained stable, delivering high single-digit growth year-over-year as the impact of prior program consolidation has largely subsided. We entered 2026 with a focus on stabilizing revenues in the first half and a goal of returning to growth in the second half, and we are delivering on that objective. Given our better-than-expected performance, we updated our full-year guidance for standalone MaxCyte in early October and are updating it further today to reflect better-than-expected commercial royalty revenue.
Total revenue is now expected to be at least $34.5 million compared to prior guidance of approximately $34 million from October, and our previous range of $30 million-$32 million, representing a total increase of $3.5 million at the midpoint since the second quarter call. This increase reflects both accelerated instrument purchases by one of our partners, the underlying strength in core revenue across our broader customer base, and stronger-than-expected SPL program advancement. Given the underlying health of the core business, we expect approximately 15% year-over-year core revenue growth in the second half, marking a meaningful return to growth following the stabilization of our business earlier this year. Combined with increased milestone and royalty contributions from our SPL partners, this return to core revenue growth positions us to deliver total revenue growth for the full year.
Turning to our partnership with Genentech, we are off to a strong start, and we are very excited about the long-term opportunity it represents for MaxCyte. As a reminder, we see this enterprise-level pharma relationship as an evolution of our partnering strategy, one that complements our SPLs rather than replacing them. Rather than licensing our technology on a program-by-program basis, we are supporting Genentech's cell therapy portfolio under a single framework across research, clinical development, and commercial manufacturing. This approach expands our presence in large pharma, allows us to participate across multiple programs, and creates opportunities to generate revenue earlier in the development lifecycle. Importantly, this partnership provides multiple avenues of revenue generation beyond instrument purchases. Over time, we expect to benefit from increased PA utilization, recurring license platform access fees, analytical services, and milestones.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
